1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD) is the most common cause of dementia in older adults, with increasing prevalence in individuals over 70 years of age. AD is characterized typically by memory impairment and neuropathological findings of beta amyloid plaques and neurofibrillary tangles ([@bb0035]). Although a definitive diagnosis currently cannot be made until autopsy, in-vivo biomarker development has emerged as a powerful tool to monitor disease progression and management ([@bb0095]; [@bb0100]) including structural magnetic resonance imaging (MRI) techniques as a clinical tool to identify stages of early cognitive decline and AD ([@bb0065]; [@bb0165]).

The hippocampus undergoes atrophic and pathological changes prior to symptomatic onset ([@bb0110]; [@bb0145]). The changes that occur in the hippocampus has even been document to impact hippocampal sub-regions differentially ([@bb0090]) ([@bb0170]). Although these differences may be due to the methods of analysis, inclusion criteria, or type of MCI, these studies indicate that characterization of hippocampal degeneration is important in stages of cognitive impairment and AD. Further, the pathological changes due to intraneuronal tau or extracellular accumulation of amyloid-β (Aβ) in the hippocampus lead to neuronal shrinkage ([@bb0130]), providing greater increase of the extracellular space.

Diffusion MRI studies have shown that individuals with MCI or AD have increased hippocampal mean diffusivity ([@bb0010]; [@bb0040]). Examining microstructural changes may be a more sensitive predictor of clinical decline than macrostructural volume measurements of the hippocampus. Recently, a new diffusion MRI technique, free water mapping, has been shown to assay extracellular space, detect neurodegeneration ([@bb0175]), and improve classification compared to single-tensor metrics ([@bb0160]). In this study, we tested the hypothesis that free-water within the hippocampus would detect differences among various stages along the AD clinical continuum and correlate with clinical severity. We also examined the extent to which free-water measures of hippocampus correlated with other measures of AD pathophysiological processes. These analyses were carried out sequentially, in two large cohorts for rigorous validation of the findings.

2. Methods {#s0010}
==========

2.1. Subjects {#s0015}
-------------

Imaging data for the current study were obtained from 2 databases: 1) the Alzheimer\'s Neuroimaging Initiative (ADNI) database and 2) the 1Florida Alzheimer\'s Disease Research Center (1Florida ADRC). ADNI has collected data through 3 phases and the ADNI data are from the ADNI 2 Phase. ADNI-2 data were used because data were collected from subjects at distinct stages of clinical severity. More details regarding the ADNI-2 protocol can be found at <https://adni.loni.usc.edu/wp-content/uploads/2008/07/adni2-procedures-manual.pdf>. The primary goal of ADNI has been to test whether serial MRI, positron emission tomography (PET), other blood and CSF markers, and clinical and neuropsychological assessment can be combined to measure the progression from the earliest mild cognitive impairment (MCI) through early Alzheimer\'s disease (AD). For up-to-date information, go to [www.adni-info.org](http://www.adni-info.org){#ir0020}. ADNI Diagnostic criteria for each clinical stage was applied to 1Florida ADRC participants. The 1Florida ADRC data are from subjects enrolled at Mount Sinai Medical Center from October 19th, 2015 to December 1st, 2017. All subjects recruited were between ages 55--90. Briefly, subjects were divided into four groups in both ADNI and 1Florida ADRC groups: 26 (ADNI; baseline age: 72.8 ± 6.6 years) and 32 (1Florida ADRC; baseline 68.9 ± 6.4 years) cognitively normal elderly controls, 45 (ADNI; baseline age: 72.7 ± 8.0 years) and 33 (1Florida ADRC; baseline 70.8 ± 7.4 years) patients with EMCI, 26 ADNI LMCI (baseline age: 73.2 ± 6.0 years) and 22 1Florida ADRC LMCI (baseline age: 74.1 ± 7.6 years), and 29 ADNI patients with AD (baseline age: 73.9 ± 8.5 years) and 25 1Florida ADRC patients with AD (baseline age: 71.5 ± 10.2 years). All participants had assessments which included a Clinical Dementia Rating-Sum of Boxes (CDR-SB) ([@bb0045]; [@bb0140]), Mini-Mental State Exam (MMSE)([@bb0085]), Montreal Cognitive Assessment (MoCA) ([@bb0150]), apolipoprotein (ApoE) ε4 status, diffusion MRI, T1 MRI, intracranial volume determination, and amyloid PET imaging data (18F-florbetapir for ADNI and 18F-florbetaben for 1Florida ADRC).

2.2. Data acquisition {#s0020}
---------------------

The Search Criteria used to acquire data identified subjects from the initial or screening visit. The ADNI T1 scans were acquired with a Gradient recalled echo (GRE) pulse sequence with acquisition in the sagittal plane, repetition time (TR) of 6.98 ms, echo time (TE) of 2.85 ms, inversion time (TI) of 400 ms, 26 cm field of view, with a 256 × 256 × 196 acquisition matrix in the *x*-, *y*-, and *z*-dimensions, yielding a voxel size of 1.0 × 1.0 × 1.2 mm^3^. 1Florida ADRC T1 scans were acquired with using a 3 T Siemens Magnetom Skyra with a 20-channel head/neck coil with a Magnetization Prepared Rapid Gradient Echo (MPRAGE) pulse sequence with acquisition in the sagittal plane, TR of 1380 ms, TE of 3.03 ms, with a 250 × 250 × 176 mm acquisition matrix in the x-, y-, and z-dimensions, yielding a voxel size of 1.0 × 1.0 × 1.0 mm^3^ (See [Table 2](#t0010){ref-type="table"}).

ADNI diffusion imaging scans were acquired with a 41 direction "EP/SE" pulse sequence b-value 1000 and 5 b0 images with a 2D acquisition, average TR of \~11,000 ms, average TE of 67 ms, flip angle of 90°, in-plane resolution = 2.7 × 2.7 mm, slice number = 59, and slice thickness = 2.7 mm with no gap and 35 cm field of view. 1Florida ADRC diffusion imaging scans were acquired with a 64 direction echo planar sequence b-value 1000 with 1 b0 image with TR of 9000 ms, TE of 90 ms, flip angle of 90°, in-plane resolution = 2 × 2 mm, slice number = 64, and a slice thickness of 2 mm with no gap (See [Table 1](#t0005){ref-type="table"}). ADNI data were acquired from 12 different scanners and 1Florida ADRC data were acquired from 1 scanner.Table 1Scanner information.Table 1ADNI1FLORIDA ADRCManufacturerGESIEMENSTypeDIFFT1DIFFT1Directions41N/A64N/ASequenceEPSEGREechoMPRAGETE672.85983.03TIN/A400 msN/A700 msTR11,0006.9890001380Flip angle90N/A09Slices5919664176FOV35 cm26 cm250 mm250 mmresolution2.7 × 2.7 × 2.71x1x1.22x2x21x1x1b-value1000N/A1000N/A\# of b06N/A1N/A[^2]

The PET scanner currently used for the 1Florida ADRC has been certified for use in ADNI. A 3D Hoffmann brain phantom was acquired prior to participant enrollment in order to establish a standardized acquisition and reconstruction method. Participants were infused with \[18-F\] florbetaben 300 MBQ over a 3 min period. Scanning commenced after a period of 60 min for a duration of 20 min on a Siemens Biograph 16 PET/CT scanner, operating in 3D mode (55 slices/frame, 3 mm slice thickness 128 × 128 matrix). Acquired PET data were reconstructed into a 128 × 128 × 63 (axial) matrix with voxel dimensions of 0.21 × 0.21 × 0.24 cm. Reconstruction was performed using manufacturer-supplied software and included corrections for attenuation, scatter, random coincidences and dead time. Images for regional analyses were processed using Fourier analysis followed by direct Fourier reconstruction. Images were smoothed with a 3 mm Hann filter. Following reconstruction, image sets were inspected and, if necessary, corrected for inter-frame motion.

2.3. Imaging processing {#s0025}
-----------------------

For each subject, all baseline raw diffusion weighted imaging (DWI) volumes were aligned with the FMRIB Software Library (FSL) eddy-correct tool (<http://www.fmrib.ox.ac.uk/fsl>) to correct for head motion and eddy-current distortions. Gradient directions were rotated based on motion corrections. All voxels outside of the brain and eye-tissue were subsequently removed from diffusion-weighted images using the Brain Extraction Tool from FSL. Free-water maps were calculated for all subjects; computational routines for free-water have been published elsewhere ([@bb0155]; [@bb0175]). All maps were warped into standardized space using ANTs R routines ([@bb0015]; [@bb0020]). First, a linear rigid transformation was performed. Then a diffeomorphic transformation using the Symmetric Normalization (SyN) transformation model was performed. SyN uses a gradient-based iterative convergence using diffeomorphisms to converge on an optimal solution based on a similarity metric (e.g., cross-correlation) ([@bb0120]). The diffeomorphic transform matrices were then applied to all the free-water maps, for subsequent analyses of hippocampal regions ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Displays coronal sections of the group mean free-water maps at y = 24 in MNI space of the hippocampus for ADNI and 1Florida ADRC across cognitive normal (CN), early mild cognitive impairment (EMCI), late mild cognitive impairment (LMCI), and Alzheimer\'s disease (AD). White-yellowish colors indicate low free-water areas whereas blue-black colors indicate high free-water areas.Fig. 1

### 2.3.1. Volumetric MRI analysis {#s0030}

Regional analysis was done on the 3D T1 MPRAGE imager with FreeSurfer (<http://surfer.nmr.mgh.harvard.edu/>) ([@bb0050]). This MRI software package is comprised of a suite of automated tools for segmentation, reconstruction, and derivation of regional volumes and surface-based rendering. FreeSurfer 6.0 was used to derive hippocampal volumes. We employed the same software version, workstation, and operating system throughout the study given known variability introduced by these factors.

### 2.3.2. PET imaging analysis {#s0035}

PET imaging data were downloaded from the ADNI website (<https://adni.loni.usc.edu>). Signal uptake value ratios (SUVRs) for amyloid-PET were calculated based on previously reported methods ([@bb0105]). The PET tracer ^18^F-florbetapir was used to quantify global amyloid status, calculated by ratios of regions of interest (ROIs) tracer retention to cerebellar and total white matter uptake. The cutoff SUVR value to determine subject status as "amyloid positive" was 1.1 using frontal lobe, anterior cingulate, precuneus, and parietal cortex relative to cerebellum. More details of the methods for the PET analyses can be found at <http://adni.loni.usc.edu/methods/pet-analysis/>.

Images were obtained from the top of the head to the top of the neck and CT data were employed for initial attenuation correction and image reconstruction in the sagittal, axial and coronal planes. The florbetaben PET/CT scans, including the outline of the skull, were co-registered linearly (i.e., trilinear interpolation) with 12 degrees of freedom, onto the volumetric MRI scan using a T1-weighted, (magnetization prepared rapid gradient echo (MP-RAGE) sequence. Region-of-interest (ROI) boundaries were manually defined using the structural MRI for anatomical reference and criteria that have been proven to provide highly reproducible outcomes ([@bb0060]). This registration process ensured that the florbetaben PET/CT image had the same accurate segmentation and parcellation as in the MRI. Atrophy correction was not used because the additional noise-error added to quantification of regional counts in the PET images.

Quantitative assessment of PET scans: Image processing was performed as previously described ([@bb1000]). The average activity was calculated in the ROIs corresponding to cerebellar gray matter and cerebral cortical regions. A composite SUVR was calculated by the ratio of the mean SUVR of the 5 cortical regions (frontal, temporal, parietal, anterior and posterior cingulate cortex regions, each region summed from left and right hemispheres) and the cerebellar gray matter ([@bb2000]).

2.4. APOE genotyping {#s0040}
--------------------

Samples were genotyped for the APOE ε2, ε3 and ε4 alleles using predesigned TaqMan SNP Genotyping Assays for SNPs rs7412 and rs429358 (Thermo Fisher Scientific, Massachusetts, USA) on the QuantStudio 7 Flex Real-Time PCR system (Applied Biosystems, California, USA) following the manufacturer\'s protocol. This genotyping allowed us to determine whether participants had e4 positive or negative. The APOE e4 allele has shown to occur in a higher prevalence in individuals with Alzheimer\'s disease than found the non-AD patients ([@bb0070]).

2.5. CSF analysis {#s0045}
-----------------

Baseline CSF samples were obtained in the morning after an overnight fast and processed as previously described ([@bb0185]; [@bb0190]). Briefly, CSF was collected into polypropylene collection tubes or syringes provided to each site, then transferred into polypropylene transfer tubes without any centrifugation step followed by freezing on dry ice within 1 h after collection, and shipped overnight to the ADNI Biomarker Core laboratory at the University of Pennsylvania Medical Center on dry ice. Aliquots (0.5 ml) were prepared from these samples after thawing (1 h) at room temperature and gentle mixing. The aliquots were stored in bar code-labeled polypropylene vials at −80 °C. Aβ~1--42~, t-tau, and p-tau~181~ were measured using the multiplex xMAP Luminex platform (Luminex Corp, Austin, TX) with Innogenetics (INNO-BIA AlzBio3; Ghent, Belgium; for research use-only reagents) immunoassay kit-based reagents.

2.6. Region of interest analyses {#s0050}
--------------------------------

ROI analyses were performed utilizing the segmented hippocampal masks that were obtained through FreeSurfer 6.0. Data from both the left and right hemispheres were obtained. These individual voxels within a ROI were then pooled together to get an average for either the left or right hippocampal region.

2.7. Statistical analyses {#s0055}
-------------------------

Measures of age, years of education, CDR-SB, MMSE, MoCA, and ICV were compared using one-way ANOVAs across the groups. Post-hoc tests of means were evaluated using the Tukey\'s HSD procedure. In order to detect differences between sites, we ran a MANCOVA on continuous demographic variables with site as a covariate. Differences in sex, amyloid status (positive or negative), and ApoE4 carrier status were assessed with Chi-square analyses separate for each site. Mean values for the hippocampal ROIs were calculated for free-water and hippocampal volume. MANCOVAs were calculated, controlling for sex, age, education, site and ApoE e4 status, with group status as the fixed factor. Post-hoc tests for the group status were evaluated using Bonferroni pairwise comparisons. Statistical threshold was set at *p* \< .05.

2.8. Correlational analyses {#s0060}
---------------------------

Spearman rho (ρ) statistic was employed for correlations between dependent free-water values and MOCA, MMSE, CSF measures and global amyloid. The Spearman rho correlations can provide information to the degree hippocampus free-water levels are associated with clinical measures along with CSF. The determination of this relationship can help further develop prediction models with longitudinal data. *P*-values were corrected for multiple comparisons controlling for false discovery rate (FDR) ([@bb0025]).

3. Results {#s0065}
==========

3.1. Demographics and clinical data {#s0070}
-----------------------------------

There were no significant differences (*p*-values\>.05) among diagnostic groups for age, sex, ICV and years of education ([Table 2](#t0010){ref-type="table"}) for either the ADNI or 1Florida ADRC cohorts. As expected, there were significant differences among groups for CDR-SB, MMSE and MoCA, scores (p-values\<.05) across both cohorts. The number of amyloid positive individuals were different among groups (p-values\<.05). For ADNI, there were more amyloid positive and ApoE ε4 carriers in the LMCI and AD groups than there were in EMCI and CN (p-values\<.01). For 1Florida ADRC there were more amyloid positive carriers in the AD than EMCI and LMCI groups, and more positive carriers in the EMCI and LMCI than CN.Table 2Demographic and clinical information.Table 2ADNI1Florida ADRCCNEMCILMCIADStatisticsCNEMCILMCIADStatisticsN26452629--29292529--Age72.8 (6.6)72.7 (8.0)73.2 (6.0)73.9 (8.5)F = 0.17, p = .9267.9 (10.0)72.8 (7.2)73.6 (7.4)72.2 (9.6)F = 2.4, p = .07Sex (M/F)12/1430/1517/916/13χ^2^ = 3.5, p = .3210/1910/1914/1116/13χ^2^ = 4.7, p = .19Years of Education16.5 (2.6)16.0 (2.6)15.5 (2.8)14.7 (2.9)F = 2.3, p = .0816.2 (3.1)15.4 (3.5)14.7 (3.3)14.0 (4.1)F = 2.05,p = .11CDR-SB0.02 (0.09)1.2 (0.7)1.6 (0.9)4.7 (1.4)F = 143.2, p = 8.5E-400.3 (0.9)0.9 (0.4)2.9 (0.9)6.7 (3.3)F = 76.3, p = 9.4E-27MMSE28.8 (1.4)28.0 (1.6)27.4 (2.0)23.6 (2.0)F = 51.3, p = 1.6E-2129.1 (1.0)27.7 (2.4)25.7 (2.7)21.4 (5.9)F = 1.6, p = 4.2E-12MoCA26.2 (2.4)23.6 (2.4)21.6 (2.3)17.8 (4.7)F = 37.2, p = 4.0E-1724.9 (2.8)23.0 (3.1)22.2 (10.1)14.2 (6.3)F = 14.57, p = 7.0E-8Amyloid Status\
(−/+)24/023/186/184/25χ2 = 41.8, p = 4.5E-925/016/613/97/15χ2 = 25.6, p = .0002ApoE ε4 Carriers (0/1+)18/728/165/209/19χ2 = 20.7, p = .000120/621/810/1319/7χ2 = 7.8, p = .05Intercranial\
Volume (L)1.41 (0.14)1.49 (0.14)1.48 (0.12)1.42 (0.16)F = 2.0, p = .1161.34 (0.13)1.36 (0.17)1.40 (0.18)1.42 (0.21)F = 1.36, p = .26[^3]

In the ADNI cohort, post-hoc tests revealed lower CDR-SB scores for controls compared to EMCI and LMCI; the AD group had the highest CDR-SB scores (see [Table 2](#t0010){ref-type="table"}). Post hoc testing revealed the following pattern of results for MoCA: CN \> EMCI \> LMCI \> AD. MMSE scores were lower for the AD group than the CN, EMCI, and LMCI groups, and higher (better) in the CN and EMCI groups than in the LMCI and AD groups (*p*-values\<.01; see [Table 2](#t0010){ref-type="table"}).

For the 1Florida ADRC cohort, post-hoc tests revealed lower CDR-SB scores for controls and EMCI when compared with LMCI and AD (see [Table 2](#t0010){ref-type="table"}). Post hoc testing revealed that AD MoCA scores were significantly lower than CN, EMCI and LMCI groups. MMSE scores decreased with increases in disease severity with CN having the highest scores and AD having the lowest scores (p-values\<.01; see [Table 2](#t0010){ref-type="table"}).

Statistical analyses also revealed the influence of the site covariate on the continuous demographic variables. We found no site effect for age (F = 0, *p* = .98), MoCA (F = 2.6, *p* = .11), MMSE (F = 2.7, p = .11). There was a significant effect for years of education with the ADNI site have more years of education than the 1Florida ADRC site (F = 14.3, *p* = 2E-4) and CDR-SB (F = 14.2,*p* = 1.9E-4) which resulted in greater scores in the 1Florida ADRC cohort.

3.2. Diffusion analyses {#s0075}
-----------------------

[Fig. 2](#f0010){ref-type="fig"}A illustrates the group free-water in MNI space at y = 24, and [Fig. 2](#f0010){ref-type="fig"}B shows the bar plots for free-water in each cohort for left hippocampus. Significant effects were found for mean free-water values in both hippocampal ROIs (F\'s \> 2.5, *p*-values\<.01) (See [Fig. 2](#f0010){ref-type="fig"}). The left hippocampal ROI (F = 16.35, *p* = 1.5E-9) revealed increased free-water values for the AD group (0.56),LMCI group (0.51) and iEMCI group (0.48) when compared to CN (0.42, p-values \<.003). EMCI group free-water values were also lower than the AD group (p = 2E-4). This pattern of findings was found to be consistent when both cohorts were analyzed separately (*p* \< 1E-5). The right hippocampal (F = 3.2, *p* = .023) revealed increased free-water for AD (0.50) when compared to CN (0.43), with no significant differences in free-water levels between the EMCI group (0.47) and the LMCI group (0.49).Fig. 2Displays bar-graphs of free-water levels for the left and right hippocampus in CN, EMCI, LMCI, and AD patients. The asterisk indicates significant differences between CN, EMCI, LMCI, and AD. The cross indicates significant differences between EMCI and AD. The pound sign indicates significant differences between LMCI and AD.Fig. 2

Statistical analyses revealed a significant covariates of age (F = 24.51, p = 2E-6) and site (F = 8.5, *p* = .004) on the left hemisphere free-water values, whereas there were significant covariate effects of age and sex for the right hemisphere free-water values (F\'s \> 2, p-values \>.05). There were no significant covariate effects for education, ApoE ε4 on either dependent variable (F\'s \> 2, p-values\>.05). The age covariate in the model showed a positive intercept indicated increases in free-water with age for the left-hemisphere free-water values. The site covariate resulted in higher values in the 1Florida ADRC cohort than the ADNI cohort. As noted above, this did not change the pattern of findings for either cohort. For the right hippocampal free-water values, age covariate (F = 6.5,*p* = .012) results in increases in free-water and sex covariate (F = 6.5,p = .012) results in decreases in free-water.

3.3. Volumetric analyses {#s0080}
------------------------

For the ADNI cohort, a significant group effect was found for all left and right hippocampal ROIs (F\'s \> 9, FDR *p* \< .01). Post hoc analysis revealed no significant differences between the CN and EMCI groups for any hippocampal ROIs (F\'s \> 9, p\'s \> 0.05). The left hippocampus (F = 24.4, *p* = 2.4E-12) volumes were significantly lower for the AD and LMCI groups when compared to the CN and EMCI groups. Right hippocampal (F = 26.9, p = 2.4E-13) showed a similar pattern of results as their left counterparts, in addition volumes for the AD group were lower than the LMCI group whereas the left side did not show a difference between these two groups.

For the 1Florida ADRC cohort, a significant group effect was also found for all left and right hippocampal volumes similar to the ADNI findings (F\'s \> 9, p\'s \< 0.01). The left hippocampus (F = 9.0, *p* = 2.2E-5) volumes were significantly lower for the AD group when compared to controls and EMCI groups. The right hippocampal (F = 10.7, *p* = 4E-6) volumes were significantly lower for the AD group when compared to controls, EMCI and LMCI groups. There were no significant covariate effects of site, education, ApoE ε4 status on volumetric measures. There was a significant effect of age on hippocampal volumetric measures. The age covariate indicates decreases in volume with increases in age.

3.4. Correlation analyses {#s0085}
-------------------------

Free-water values from both hippocampal ROIs were correlated with MMSE and MoCA ([Table 3](#t0015){ref-type="table"}). Significant negative associations were found among all ROIs with MMSE and MoCA.Table 3Correlational analyses of free-water, CSF, PET imaging, and clinical measures.Table 3MMSEMoCAAV45CSF Aβ~1--42~CSF p-tauCSF t-tauρFDR P-valueρFDR P-valueρFDR P-valueρFDR P-valueρFDR P-valueρFDR P-valueLeft Hippocampus Free-water−0.45^⁎^8.90E-06−0.38^⁎^0.0050.30^⁎^8.60E-03−0.28^⁎^0.0040.090.470.210.06RightHippocampus Free-water−0.42^⁎^8.60E-06−0.42^⁎^3.45E-040.27^⁎^0.003−0.27^⁎^0.0080.110.360.130.27[^4]

Correlations between free-water measures and amyloid PET data revealed several significant relationships. All regions were found to positively correlate with AV45 with the left hippocampal free-water levels demonstrating the greatest correlation among ROIs.

Correlational analyses between CSF measures and free-water levels revealed several significant correlations. For free-water, left and right hippocampus regions were found to moderately correlate inversely with CSF AB~1--42~ levels. There were no significant correlations between free-water levels and p-tau or t-tau (*p* \> .05) (See [Table 3](#t0015){ref-type="table"}).

4. Discussion {#s0090}
=============

The current investigation examined the integrity of hippocampal regions by assessing free-water imaging in different stages of AD across ADNI and the 1Florida ADRC. The results indicate that left hippocampal free-water values were elevated in EMCI when compared to CN, across both the ADNI and 1Florida ADRC cohorts. ADNI free-water measures from both hemispheres correlated with clinical cognition scores. In addition, free-water values were associated with global AV45 and CSF AB~1--42~ levels and not CSF p-tau and CSF t-tau, suggesting free-water may provide specific information about the pathological process in AD. Thus, the current study suggests that free-water mapping of bilateral hippocampus provides important information of neurodegenerative changes in AD.

Previous studies have shown that elevated mean diffusivity (MD) in the hippocampus is a precursor to symptomatic AD and can detect early stage changes of AD ([@bb0075]). It has been suggested that this elevation in MD is due to increased extracellular water content or decreased gray matter density ([@bb0075]). Our findings extend previous work suggesting diffusion metrics are elevated in the hippocampus, and that they are more sensitive to hippocampal change than volumetric imaging. It is important to note that we used Freesurfer 6.0 which has improved segmentation for volume, and free-water remained more sensitive to left hippocampal change in early MCI for both cohorts. Although, we found increases in left and right free-water measures from the hippocampus between CN and EMCI, in both ADNI and ADRC cohorts, volumetric measures between CN and EMCI revealed no detectable changes in these same regions. The current results suggest that changes occurring early in the AD pathophysiological process may relate to microstructural changes in the left hippocampus. Coincidentally, there were inverse correlations between free-water levels in bilateral hippocampus and CSF AB~1--42~ levels; whereas free-water levels were not associated with CSF total tau. Further, higher levels of free-water were associated with lower scores on the MMSE and the MoCA. These findings support the hypothesis that increased levels of free water in these hippocampal ROIs have functional and clinical relevance in the AD process, and may be among the earliest detectable structural changes. Pyramidal neuron loss within the hippocampus results in the connections to disconnect from their projection areas in the cortex ([@bb0055]; [@bb0170]). In a previous MRI study, it was reported that the greatest atrophy in the hippocampus occurred shows a systematic decline within the regiony ([@bb0090]). Nonetheless, the current study using diffusion imaging showed the hippocampal free-water values were elevated in EMCI patients. Free-water is suggested to estimate the size of the extracellular space and reflect the degenerative processes that occur in this area. There is some support for the hypothesis that the changes seen within these particular hippocampal regions are due to cholinergic and glutamatergic terminal loss from the nucleus basalis and lamina II of the entorhinal cortex (ERC) respectively ([@bb0125]). In a previous study demonstrated densities of choline acetyltransferase-positive punctate immunoprecipitates were found to be significantly higher in hippocampal areas for AD ([@bb0180]) and that the neurofibrillary pathology first affects lamina II ERC neurons ([@bb0030]). The loss of cholinergic modulation in AD may contribute to a decline in memory.

Previous studies have shown correlations between cognitive measures and volumetric measures of hippocampus ([@bb0135]). The current study shows significant correlations between free-water from all hippocampal ROIs and various cognitive assessment scores. Our findings also support the hypothesis that MRI markers of cognitive impairment follow closely with clinical symptoms ([@bb0080]). This is consistent with prior findings that demonstrate correlations between hippocampal MD and F DG-PET ([@bb0005]). This may provide potential information to determine whether free-water may be used as a progression marker for AD and MCI. Although longitudinal confirmation would be required, if these findings are confirmed, they may provide a sensitive marker of the effects of therapeutic intervention, similar to the proposed use of free-water in Parkinson\'s disease ([@bb3000]). Postmortem studies demonstrate accumulation of intraneuronal tau in the hippocampus from midlife onward ([@bb0035]). This is associated with inflammatory reactions and neuronal atrophy, and potentially larger amounts of extracellular fluid--which in turn may relate to higher free-water content.

We note three limitations that could influence the reported results. One, site differences between the cohorts could confound some of the reported results. We did covary for site to minimize this influence however as noted above the influence of site on some demographic and imaging variables requires further study. Further, more comprehensive neuropsychological test data would aid in characterization of the patient status. Finally, baseline data were only included and longitudinal data would help confirm the extent diagnoses, hippocampal imaging findings and potential changes in diagnoses are influenced by cross-sectional differences in the hippocampal free-water.

The current study found free-water levels were positively associated with global levels of AV45 and negatively associated with CSF Aß42, which correlates negatively with amyloid deposition in the brain ([@bb0115]; [@bb0195]). However, free-water levels did not correlate with CSF p-tau or CSF t-tau in our study, suggesting the possibility that the increase in free water levels may reflect amyloid- induced prodromal neurodegenerative changes in the hippocampus occurring prior to the increase in CSF tau. This hypothesis is supported by the known time course of events, which have been validated in longitudinal studies, showing that increases in brain amyloid levels precede increases in CSF tau by a decade or more ([@bb0095]). In summary, our study suggests that free-water values from the hippocampus may reflect a pathophysiological process along the entire AD continuum, in the presence of increased global amyloid deposition, but prior to overt evidence of neurodegeneration in the form of hippocampal atrophy or increased CSF tau increases. We found evidence that hippocampal free-water values served as a very early marker of cognitive impairment with changes detected in EMCI, in two separate large cohorts. We suggest that hippocampal free-water levels provide distinct and sensitive in-vivo information about AD neurodegeneration.
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[^1]: Data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#ir0005}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>.

[^2]: Abbreviations: DIFF = diffusion, EPSE = echo-planar spin-echo, FOV = field of view, GE = General Electric, GRE = gradient echo, MP-RAGE = magnetization prepared-rapid acquisition gradient echo, N/A = not available, TI = inversion time, TE = echo time, TR = repetition time.

[^3]: Data are either count or mean (±SD). Abbreviations: AD = Alzheimer\'s disease, ApoE = apolipoprotein, CDR-SB = clinical dementia rating- sum of boxes, CN = Cognitively Normal, EMCI = Early Mild Cognitive Impairment, F = female, ICV = Intracranial Volume, L = Liters, LMCI = Late Mild Cognitive Impairment, M = male, MMSE = Mini-Mental State Examination, MoCA = Montreal Cognitive Assessment.

[^4]: The correlation coefficients and the corresponding *p* value are listed for each association, \*indicates significant correlations (FDR *p* \< .05). Abbreviations: Aβ = amyloid beta, AV45 = florbetapir, CSF = cerebrospinal fluid, MMSE = Mini-Mental State Examination, MoCA = Montreal Cognitive Assessment, p-tau = phosphorylated tau, and t-tau = total tau.
